Sun Pharmaceutical Industries Limited

Sector: Pharmaceuticals  |  HQ: Mumbai, Maharashtra  |  Founded: 1983  |  Employees: ~38,000

Listed as: NSE / BSE listed; Nifty 50 constituent; India's largest pharma company by revenue  |  NSE / BSE  |  Ticker: SUNPHARMA.NS  |  Website →

Key people

• Dilip Shanghvi (Managing Director and Founder)

Company overview

Sun Pharmaceutical Industries Limited is India's largest pharmaceutical company by revenue and the world's fourth-largest generic pharmaceutical company. Founded in 1983 by Dilip Shanghvi in Vapi, Gujarat, the company is headquartered in Mumbai and operates 41 manufacturing facilities across India, the United States, Israel, Romania, Bangladesh, Egypt, Hungary, Malaysia, Mexico, Morocco, Nigeria, Russia, Brazil, and Canada. FY25 consolidated revenue was approximately USD 6.4 billion (₹53,500 crore) with PAT of approximately ₹10,400 crore. Sun Pharma sells specialty and generic medicines in 100+ countries.

Business model

Sun Pharma operates four reporting segments. Domestic Formulations (India branded generics) is the largest by EBIT contribution with brands across chronic therapy categories (cardiovascular, anti-diabetic, neuro-psychiatric, oncology, respiratory). US Generics is the second-largest revenue segment, sold under Sun Pharmaceutical Industries Inc. and the acquired Taro Pharmaceutical (NYSE: TARO until its delisting in 2025). The Specialty branded portfolio (Ilumya for psoriasis, Cequa for dry eye, Winlevi for acne, Odomzo for skin cancer) is the higher-margin growth driver. Emerging Markets and Active Pharmaceutical Ingredients (API) round out the segment portfolio.

Operating segments

Recent developments

May 2026

Sun Pharmaceutical Industries has executed a landmark strategic move, signing a definitive agreement to acquire Organon in a $11.75 billion transaction [3][7]. This represents the company's largest acquisition in recent history and signals a significant push into the global women's health and biosimilar markets. Major legal advisors including White & Case, AZB, Sullivan, Cyril Amarchand Mangaldas, TT&A and Linklaters are advising on the deal [7]. The acquisition positions Sun Pharma for substantial scale and geographic diversification beyond its core specialty generics business.

On the capital markets front, LIC increased its stake in Sun Pharma to cross the 5% regulatory threshold [8], underscoring institutional confidence in the pharma major. Meanwhile, an analyst note suggests the share price may not fully reflect underlying fundamentals [5], hinting at potential undervaluation or market skepticism regarding valuation multiples. Separately, Sun Pharma announced plans to invest Rs 500 crore in its Assam manufacturing unit [6], indicating continued capacity expansion to support future growth.

Sources (5)

1. Sun Pharma signs Definitive Agreement to Acquire Organon - Business Wire · Business Wire · Sun, 26 Apr 2026
2. Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Share Price Not Quite Adding Up - simplywall.st · simplywall.st · Fri, 30 Jan 2026
3. Sun Pharma to pump in Rs 500 cr in Assam manufacturing unit - ETPharma.com · ETPharma.com · Thu, 05 Feb 2026
4. White & Case, AZB, Sullivan, Cyril Amarchand Mangaldas, TT&A, Linklaters act on Sun Pharma's $11.75 billion acquisition of Organon - Bar and Bench · Bar and Bench · Mon, 27 Apr 2026
5. Sun Pharma Sees LIC Cross 5% Holding Threshold - Medical Dialogues · Medical Dialogues · Thu, 15 Jan 2026

Financial performance and recent trajectory

Sun Pharma reported FY25 consolidated revenue of approximately ₹53,500 crore with EBITDA of ₹15,800 crore. EBITDA margin in the high-20s reflects the specialty-branded mix shift and the operating leverage on the India and emerging markets businesses. R&D spend is approximately 6 to 7 percent of revenue. Capital expenditure is ₹1,500 to ₹2,000 crore per year. The balance sheet is debt-light post Taro delisting.

Stock performance and shareholder context

Sun Pharmaceutical (NSE: SUNPHARMA, BSE: 524715) is a Nifty 50 constituent. The Shanghvi family holds approximately 54 percent. The stock has delivered strong returns over the FY23-FY25 window as the specialty franchise scaled and the US generics business stabilised post the FDA inspection cycle.

12-month price trajectory

Monthly closes over the last 12 months. Source: Yahoo Finance.

Competitive position

In India, Sun Pharma leads the domestic branded generics market with approximately 8 to 9 percent share, ahead of Cipla, Dr Reddy's, Mankind Pharma, Torrent Pharma, and Alkem Laboratories. In US generics, the principal competitors are Teva Pharmaceutical, Sandoz (Novartis), Mylan-Viatris, and Indian peers Dr Reddy's and Aurobindo Pharma. The specialty branded portfolio is the differentiated growth driver.

Key risks

US FDA inspection findings on Indian manufacturing facilities; specialty drug development pipeline execution; patent expiry and competition; pricing pressure in US generics; India domestic price regulation (NPPA orders); INR-USD volatility on export revenue.

Outlook

Strong outlook on the specialty branded portfolio expansion through FY30 with new launches in oncology, dermatology, and ophthalmology. India domestic remains the stable base. New entrants in pharma manufacturing benchmark against Sun Pharma's scale, regulatory excellence, and capital allocation discipline.

KAMRIT point of view

Building or competing with Sun?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharmaceuticals sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Sun and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 2 related project reports → Book a scoping call

Related KAMRIT project reports

These reports use Sun Pharmaceutical Industries Limited in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.